Dosing and Administration Wegovy is administered as a once-weekly subcutaneous injection, typically starting at a lower dose of 0.25 mg, which can be gradually increased based on individual needs and tolerability
O uso do medicamento durante o perodo de amamentao tambm no recomendado.13
In contrast, semaglutide, despite its widespread clinical use for glycemic control and weight loss, showed minimal interaction with neurodegenerative pathways within the DM2-AD comorbidity network, suggesting that its metabolic benefits may not translate into AD risk reduction through core disease-associated mechanisms
B., Fu, X., Wu, Y., Li, L., Smith, J
Keep them in the original vial, protected from light
Similarly, in the SURMOUNT-1 trial, all participants received lifestyle intervention which included regular counseling with a dietitian or qualified health professional to achieve a 500 kcal/day energy deficit and 150 minutes of physical activity weekly